CAS 607723-33-1

Lobeglitazone

Description:

Lobeglitazone is a synthetic compound classified as a thiazolidinedione, primarily used in the management of type 2 diabetes mellitus. It functions as a selective agonist for peroxisome proliferator-activated receptor gamma (PPAR-γ), which plays a crucial role in glucose and lipid metabolism. Lobeglitazone enhances insulin sensitivity, thereby improving glycemic control in diabetic patients. The compound is characterized by its ability to modulate gene expression involved in glucose and fat metabolism, leading to reduced insulin resistance. Additionally, it has anti-inflammatory properties, which may contribute to its therapeutic effects. Lobeglitazone is typically administered orally and is known for its favorable safety profile compared to other agents in its class. However, like other thiazolidinediones, it may be associated with potential side effects, including weight gain and fluid retention. Its chemical structure includes a thiazolidinedione ring, which is essential for its biological activity. Overall, Lobeglitazone represents a valuable option in the pharmacological management of type 2 diabetes, particularly for patients who require improved insulin sensitivity.

Formula: C₂₄H₂₄N₄O₅S

InChI: InChI=1S/C24H24N4O5S/c1-28(21-14-22(26-15-25-21)33-19-9-7-17(31-2)8-10-19)11-12-32-18-5-3-16(4-6-18)13-20-23(29)27-24(30)34-20/h3-10,14-15,20H,11-13H2,1-2H3,(H,27,29,30)

InChI key: InChIKey=CHHXEZSCHQVSRE-UHFFFAOYSA-N

SMILES: O(C=1C=C(N(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C)N=CN1)C4=CC=C(OC)C=C4

Synonyms:

• Lobeglitazone
• 5-[[4-[2-[[6-(4-Methoxyphenoxy)-4-pyrimidinyl]methylamino]ethoxy]phenyl]methyl]-2,4-thiazolidinedione
• 2,4-Thiazolidinedione, 5-[[4-[2-[[6-(4-methoxyphenoxy)-4-pyrimidinyl]methylamino]ethoxy]phenyl]methyl]-
• (5R)-5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
• 2,4-Thiazolidinedione, 5-[[4-[2-[[6-(4-methoxyphenoxy)-4-pyrimidinyl]methylamino]ethoxy]phenyl]methyl]-
• 5-[4-[2-[[6-(4-Methoxyphenoxy)pyrimidin-4-yl]methylamino]ethoxy]benzyl]thiazolidine-2,4-dione

5-(4-(2-((6-(4-Methoxyphenoxy)pyrimidin-4-yl)(methyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione

CAS: 607723-33-1

5-(4-(2-((6-(4-Methoxyphenoxy)pyrimidin-4-yl)(methyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione

Purity: 98%

Molecular weight: 480.55g/mol

Ref: 54-OR1067827

Lobeglitazone

CAS: 607723-33-1

Formula: C₂₄H₂₄N₄O₅S

Molecular weight: 480.54

Ref: 4Z-L-179001

Lobeglitazone

CAS: 607723-33-1

Lobeglitazone (CKD-501) is a dual PPARα/γ agonist thiazolidinedione antidiabetic that enhances insulin sensitivity.

Formula: C₂₄H₂₄N₄O₅S

Color and Shape: Solid

Molecular weight: 480.54

Ref: TM-T69011

Lobeglitazone-d3

Controlled Product

CAS: 607723-33-1

Formula: C₂₄D₃H₂₁N₄O₅S

Color and Shape: Neat

Molecular weight: 483.555

Ref: TR-L242432

Lobeglitazone

Controlled Product

CAS: 607723-33-1

Formula: C₂₄H₂₄N₄O₅S

Color and Shape: Neat

Molecular weight: 480.536

Ref: TR-L242430

Lobeglitazone

CAS: 607723-33-1

Lobeglitazone is a dipeptidyl peptidase-4 (DPP-4) inhibitor that stimulates glucagon-like peptide-1 receptor (GLP-1R). It is used for the treatment of type 2 diabetes and has been shown to inhibit the proliferation of vascular smooth muscle cells and reduce atherosclerotic lesion size. Lobeglitazone also has an effect on matrix metalloproteinases, which may be related to its ability to inhibit the development of renal fibrosis. Lobeglitazone modulates energy metabolism by increasing insulin sensitivity and reducing insulin levels in blood. This drug also reduces blood pressure and prevents congestive heart failure by lowering blood pressure and improving left ventricular function. The concentration–time curve of lobeglitazone can be monitored with a test that measures serum concentrations every 15 minutes for 24 hours after administration. Lobeglitazone should not be taken by people with metabolic disorders or kidney dysfunction.

Purity: Min. 95%

Ref: 3D-FL176227